The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | Moving CAR-T therapy into earlier lines of treatment for myeloma and the need for effective bridging
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the excitement around advancing CAR-T therapies into earlier lines of treatment in multiple myeloma (MM), driven by promising results from the KarMMa-3 (NCT03651128) and CARTITUDE-4 (NCT04181827) trials investigating idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), respectively. Both trials demonstrated significantly improved progression-free survival (PFS) in the CAR-T arm compared to standard of care (SoC). While emphasizing the need for enhanced bridging therapy before CAR-T, Prof. Mohty points out that progress in bispecific antibodies may address this challenge. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; GSK: Honoraria; Pfizer; Honoraria; Adaptive Biotechnologies: Honoraria; Oncopeptides: Honoraria; Astellas: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Celgene: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
